The long-awaited study, which was commissioned by the FDA in hopes of reducing racial bias, found results that contradict past research findings, leaving clinicians confused. Also: FDA Commissioner ...
Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 -- ...
LSD is a drug often associated with the counter-culture of the 1960s. But it is being studied as a promising therapy for ...
In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked ...
Definium’s late-stage pipeline includes four Phase 3 trials—two each for GAD and MDD—anchored by its lead candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD.
San Francisco’s UCSF is stepping into the national spotlight as one of several university medical centers testing whether a ...
UCSF is seeking volunteers for a trial using LSD to treat generalized anxiety disorder - a poorly understood and potentially ...
The results from drugmaker Mindmed tested several doses of LSD in patients with moderate-to-severe generalized anxiety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback